Literature DB >> 16393465

Carbamazepine uptake into rat brain following intra-olfactory transport.

N S Barakat1, S A Omar, A A E Ahmed.   

Abstract

Targeting the brain via nasal administration of drugs has been studied frequently over the last few years. In this study, a suitable gel formulation was designed to provide the absorption of a highly lipophilic drug through nasal mucosa. For this purpose, carbamazepine was chosen as the model drug. Hypromellose and Carbopol were used as mucoadhesive polymers in the formulation to increase the residence time of the gel on the mucosa. The objective of this study was to confirm the existence of a transport pathway for a drug (carbamazepine) to the brain directly from the nasal cavity, by comparing the concentration of drug in the brain after intranasal (i.n.), intravenous (i.v.), and oral (p.o.) administration. A statistically significant high level of the drug was found in the brain following intranasal administration compared with the intravenous and oral routes. These findings suggested the existence of a direct transport pathway for carbamazepine from the nasal cavity to the brain. This pathway may represent a new delivery route to the brain and central nervous system of such drugs which are needed in high and rapid concentration in the brain, especially in emergencies.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16393465     DOI: 10.1211/jpp.58.1.0008

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  13 in total

1.  Trigeminal pathways deliver a low molecular weight drug from the nose to the brain and orofacial structures.

Authors:  Neil J Johnson; Leah R Hanson; William H Frey
Journal:  Mol Pharm       Date:  2010-06-07       Impact factor: 4.939

2.  Patient-Friendly, Olfactory-Targeted, Stimuli-Responsive Hydrogels for Cerebral Degenerative Disorders Ensured > 400% Brain Targeting Efficiency in Rats.

Authors:  Noha Nafee; Abd El Rahman Ameen; Osama Y Abdallah
Journal:  AAPS PharmSciTech       Date:  2020-11-22       Impact factor: 3.246

3.  Sulfobutyl ether(7) β-cyclodextrin (SBE(7) β-CD) carbamazepine complex: preparation, characterization, molecular modeling, and evaluation of in vivo anti-epileptic activity.

Authors:  Ankitkumar S Jain; Abhijit A Date; Raghuvir R S Pissurlenkar; Evans C Coutinho; Mangal S Nagarsenker
Journal:  AAPS PharmSciTech       Date:  2011-09-15       Impact factor: 3.246

Review 4.  A Historical Review of Brain Drug Delivery.

Authors:  William M Pardridge
Journal:  Pharmaceutics       Date:  2022-06-16       Impact factor: 6.525

5.  CNS Delivery and Anti-Inflammatory Effects of Intranasally Administered Cyclosporine-A in Cationic Nanoformulations.

Authors:  Sunita Yadav; Grishma Pawar; Praveen Kulkarni; Craig Ferris; Mansoor Amiji
Journal:  J Pharmacol Exp Ther       Date:  2018-12-27       Impact factor: 4.030

6.  Brain delivery of valproic acid via intranasal administration of nanostructured lipid carriers: in vivo pharmacodynamic studies using rat electroshock model.

Authors:  Sharareh Eskandari; Jaleh Varshosaz; Mohsen Minaiyan; Majid Tabbakhian
Journal:  Int J Nanomedicine       Date:  2011-02-15

7.  Microdialysis in awake macaque monkeys for central nervous system pharmacokinetics.

Authors:  Thibaud Thiollier; Caisheng Wu; Gregory Porras; Erwan Bezard; Qin Li; Jinlan Zhang; Hugues Contamin
Journal:  Animal Model Exp Med       Date:  2018-12-04

8.  Intranasal administration of carbamazepine-loaded carboxymethyl chitosan nanoparticles for drug delivery to the brain.

Authors:  Shanshan Liu; Shili Yang; Paul C Ho
Journal:  Asian J Pharm Sci       Date:  2017-09-12       Impact factor: 6.598

9.  Brain Targeting of Acyl-CoA:Cholesterol O-Acyltransferase-1 Inhibitor K-604 via the Intranasal Route Using a Hydroxycarboxylic Acid Solution.

Authors:  Kimiyuki Shibuya; Shigeru Morikawa; Masayoshi Miyamoto; Shin-Ichiro Ogawa; Yoshihiko Tsunenari; Yasuomi Urano; Noriko Noguchi
Journal:  ACS Omega       Date:  2019-10-02

Review 10.  Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease.

Authors:  Leah R Hanson; William H Frey
Journal:  BMC Neurosci       Date:  2008-12-10       Impact factor: 3.288

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.